Protara Therapeutics
TARA
36 hedge funds and large institutions have $43.7M invested in Protara Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 11 closing their positions.
1,427% more call options, than puts
Call options by funds: $168K | Put options by funds: $11K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
7.17% less ownership
Funds ownership: 63.33% → 56.16% (-7.2%)
12% less funds holding
Funds holding: 41 → 36 (-5)
37% less capital invested
Capital invested by funds: $69.3M → $43.7M (-$25.6M)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$877K |
| 2 |
Two Sigma Advisers
New York
|
+$861K |
| 3 |
Two Sigma Investments
New York
|
+$589K |
| 4 |
Renaissance Technologies
New York
|
+$503K |
| 5 |
Goldman Sachs
New York
|
+$185K |
Top Sellers
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$6.75M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$3.41M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$817K |
| 4 |
Millennium Management
New York
|
-$191K |
| 5 |
Morgan Stanley
New York
|
-$174K |
TARA Hedge Fund Activity: Q3 2021 in Review
36 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2021, worth a combined $43.7M — down 37% from $69.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TARA and 6 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 11 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $877K. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $6.75M sold.
- 36 institutional investors held Protara Therapeutics (TARA) as of Q3 2021, down from 41 in Q2 2021.
- Funds reported $43.7M of Protara Therapeutics stock for Q3 2021, down 37% quarter-over-quarter.
- 6 funds opened new Protara Therapeutics positions in Q3 2021 and 11 closed out, a net change of -5 holders.
- The largest Protara Therapeutics buyer in Q3 2021 was Bridgeway Capital Management, an estimated $877K added.
- The largest Protara Therapeutics seller in Q3 2021 was Rock Springs Capital Management, an estimated $6.75M sold.
Based on aggregated 13F filings for Q3 2021.